Jump to ContentJump to Main Navigation
Show Summary Details
More options …

The EuroBiotech Journal


4 Issues per year

Open Access
See all formats and pricing
More options …

Nutraceutical prospective: The synergetic mechanism of action of inositols and resveratrol on metabolic syndrome

Antonio Malvasi
  • Department of Obstetric & Gynecology, Santa Maria Hospital, GVM Care & Research, Bari, Italy; Laboratory of Human Anatomy, Department of Applied Mathematics, Moscow Institute of Physics and Technology (State University), Moscow Region, Russian Federation
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Andrea Tinelli
  • Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce, Italy
  • Laboratory of Human Physiology, Phystech BioMed School, Faculty of Biological & Medical Physics, Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, Russian Federation
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Domenico Baldini / Rossana G. Iannitti
  • Department of Chemistry, Biology and Biotechnology, Via Elce di sotto, 06123, University of Perugia, Perugia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Bernard Fioretti
  • Corresponding author
  • Department of Chemistry, Biology and Biotechnology, Via Elce di sotto, 06123, University of Perugia, Perugia, Italy
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-02-06 | DOI: https://doi.org/10.2478/ebtj-2018-0006


It has been known that inositols function as insulin second messengers and mediate different insulin-dependent processes and are a valid natural, non-pharmaceutical alternative to contrast insulin-resistance as well as associated metabolic syndrome in women with Polycystic ovarian disease (PCOS). Several studies also have shown positive effects of resveratrol in reducing glucose and lipid concentrations in patients. Recently, clinical evidence has proven that an D-chiro-inositol/resveratrol combination has a potential role to play in maintaining metabolic and endocrine health, however no large clinical trials have demonstrated the medical effectiveness of the combination, and the combined mode of action remains poorly discussed. Herein, we address the hypothesis of a synergistic mechanism adopted by D-chiro-inositol and resveratrol in reducing insulin resistance and hyperlipidemia and thus showing a greater therapeutic potential compared to treatment with inositol’s alone.

Keywords: resveratrol; inositols; insulin and metabolic syndrome


  • 1. Iqbal J, Al Qarni A. Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Curr Diabetes Rev. 2017 Jul 5.Google Scholar

  • 2. Chen C, Jing G. Insulin resistance and polycystic ovary syndrome in a chinese population. Endocr Pract. 2017 Jul 6.CrossrefGoogle Scholar

  • 3. Leite PB, Dâmaso AR. Long-term interdisciplinary therapy decreases symptoms of binge eating disorder and prevalence of metabolic syndrome in adults with obesity. Nutr Res. 2017 Apr;40:57-64.Google Scholar

  • 4. Al-Dughaishi T, Nikolic D. Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome. Curr Pharm Biotechnol. 2016;17(7):614-23.Web of ScienceCrossrefGoogle Scholar

  • 5. Dong D, Reece EA. New development of the yolk sac theory in diabetic embryopathy: molecular mechanism and link to structural birth defects. Am J Obstet Gynecol. 2016 Feb;214(2):192-202.Google Scholar

  • 6. Greene ND, Leung KY, Copp AJ. Inositol, neural tube closure and the prevention of neural tube defects. Birth Defects Res. 2017 Jan 30;109(2):68-80.Google Scholar

  • 7. Farren M, Daly N. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care. 2017 Jun;40(6):759-763.Web of ScienceCrossrefGoogle Scholar

  • 8. Brown J, Crawford TJ. Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes. Cochrane Database Syst Rev. 2016 Sep 7;9:CD012048.Web of ScienceGoogle Scholar

  • 9. Malvasi A, Casciaro F. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18(2):270-4Google Scholar

  • 10. Singh CK, Kumar A. Diabetic complications in pregnancy: is resveratrol a solution? Exp Biol Med (Maywood). 2013 May;238(5):482-90.Web of ScienceGoogle Scholar

  • 11. Malvasi A, Kosmas I. Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients? Clin Ter. 2017 Jul-Aug;168(4):e240-e247.Google Scholar

  • 12. Timmers S, Konings E. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov 2;14(5):612-22.CrossrefGoogle Scholar

  • 13. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop GroupFertil Steril. 2012 Jan;97(1):28-38.e25.Google Scholar

  • 14. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003 Jun;46(2):325-40. Review. CrossrefGoogle Scholar

  • 15. Højlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J. 2014 Jul;61(7):B4890. Review.Google Scholar

  • 16. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update.. Reprod Biol Endocrinol. 2016 Jul 16;14(1):38Google Scholar

  • 17. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17-33.Web of ScienceCrossrefGoogle Scholar

  • 18. Toprak S, Yönem A, Cakir B, Güler S, Azal O, Ozata M, Corakçi A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res. 2001;55(2):65-70.Google Scholar

  • 19. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3: 47-60.Google Scholar

  • 20. Nestler J, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 2015; 31: 501-505.Web of ScienceGoogle Scholar

  • 21. Larner J, Huang LC, Tang G, Suzuki S, Sch wartz CF, Romero G, Roulidis Z, Zeller K, Shen TY , Oswald AS. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol 1988; 53: 965-97.Google Scholar

  • 22. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation. 1999;103(2):253-259.Google Scholar

  • 23. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O.Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol. 2016;2016:6306410.Google Scholar

  • 24. Pizzo A, Lagan`a AS, and Barbaro A, Comparison betweeneffects ofmyo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS, Gynecological Endocrinology 2014; 30 (3), 205-208.CrossrefGoogle Scholar

  • 25. Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-J O-Kon. Polygonum cuspidatum Sieb Et Zucc Yakugaku Zasshi 1963; 83 988-990.CrossrefGoogle Scholar

  • 26. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW,. Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan, Nature 2003; 425 191-196.Google Scholar

  • 27. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010 Mar;59(3):554-63.Google Scholar

  • 28. Hardie DG. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262.Google Scholar

  • 29. Chung JH, Manganiello V, Dyck JR. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol. 2012; 22(10):546-54.Web of ScienceGoogle Scholar

  • 30. Zang M. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55, 2180-2191. Google Scholar

  • 31. Chan V, Fenning A, Iyer A, Hoey A, Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Current Pharmaceutical Biotechnology. 2011;12(3):429-436.Web of ScienceCrossrefGoogle Scholar

  • 32. Joshi MS, Williams D, Horlock D, Samarasinghe T, Andrews KL, Jefferis AM, Berger PJ, Chin-Dusting JP, Kaye DM. Role of mitochondrial dysfunction in hyperglycaemia-induced coronary microvascular dysfunction: Protective role of resveratrol. Diab Vasc Dis Res. 2015 May;12(3):208-16.Web of ScienceGoogle Scholar

  • 33. Zhu KN, Jiang CH. Two triterpeniods from Cyclocarya paliurus (Batal) Iljinsk (Juglandaceae) promote glucose uptake in 3T3-L1 adipocytes: The relationship to AMPK activation. Phytomedicine. 2015 Aug 15;22(9):837-46.Google Scholar

  • 34. Wang S, Song P, Zou MH. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond). 2012 Jun;122(12):555-73.Web of ScienceGoogle Scholar

About the article

Published Online: 2018-02-06

Published in Print: 2018-01-01

Citation Information: The EuroBiotech Journal, Volume 2, Issue 1, Pages 35–38, ISSN (Online) 2564-615X, DOI: https://doi.org/10.2478/ebtj-2018-0006.

Export Citation

© 2018. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. BY-NC-ND 4.0

Comments (0)

Please log in or register to comment.
Log in